Details for Patent: 7,579,449

Which drugs does patent 7,579,449 protect, and when does it expire?

Patent 7,579,449 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.

Protection for SYNJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-four patent family members in thirty-six countries.

Summary for Patent: 7,579,449

Title:	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Abstract:	Glucopyranosyl-substituted benzene derivatives of general formula I ##STR00001## where the groups R.sup.1 to R.sup.6 as well as R.sup.7a, R.sup.7b, R.sup.7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
Inventor(s):	Eckhardt; Matthias (Biberach, DE), Eickelmann; Peter (Mittelbiberach, DE), Himmelsbach; Frank (Mittelbiberach, DE), Barsoumian; Edward Leon (Toyonaka, JP), Thomas; Leo (Biberach, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	11/080,150
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,579,449
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,579,449

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No					Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No					Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-003	Dec 9, 2016		RX	Yes	No					Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 7,579,449

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2004 012 676	Mar 16, 2004
Germany	10 2004 040 168	Aug 18, 2004
Germany	10 2004 061 145	Dec 16, 2004
	05002628	Feb 9, 2005

International Family Members for US Patent 7,579,449

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1730131		62/2014	Austria
European Patent Office	1730131		C300696	Netherlands
European Patent Office	1730131		PA2014035	Lithuania
European Patent Office	1730131		92555	Luxembourg
European Patent Office	1730131		CA 2014 00054	Denmark
European Patent Office	1730131		1490061-7	Sweden